Kiora Pharmaceuticals
KPRX
16 hedge funds and large institutions have $4.45M invested in Kiora Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
14% more funds holding
Funds holding: 14 → 16 (+2)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
20% less capital invested
Capital invested by funds: $5.57M → $4.45M (-$1.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$11.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.86K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$16.2K |
| 2 |
AG
Advisor Group
Phoenix,
Arizona
|
-$1.48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $4.28M | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $53K | +$60.5K | +41 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $39K | +$8.86K | +6 | +25% |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $23K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $14K | +$14.8K | +10 | +1,000% |
|
6
US Bancorp
Minneapolis,
Minnesota
| $10K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $10K | +$11.8K | +8 | New |
|
|
GSWM
8
Golden State Wealth Management
Santa Ana,
California
| $6K | – | – | – |
|
|
WS
9
Wedbush Securities
Los Angeles,
California
| $4K | – | – | – |
|
|
10
Acadian Asset Management
Boston,
Massachusetts
| $4K | +$2.95K | +2 | +200% |
|
|
VF
11
Virtu Financial
New York
| $3K | -$16.2K | -11 | -79% |
|
|
AG
12
Advisor Group
Phoenix,
Arizona
| $3K | -$1.48K | -1 | -25% |
|
13
Northern Trust
Chicago,
Illinois
| $3K | – | – | – |
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
LTFS
15
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
16
Morgan Stanley
New York
| $1K | – | – | – |
|
KPRX Hedge Fund Activity: Q2 2019 in Review
16 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2019, worth a combined $4.45M — down 20% from $5.57M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KPRX positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $60.5K. The largest seller was Virtu Financial, cutting an estimated $16.2K.
- 16 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2019, up from 14 in Q1 2019.
- Funds reported $4.45M of Kiora Pharmaceuticals stock for Q2 2019, down 20% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q2 2019 and 0 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2019 was Susquehanna International Group, an estimated $60.5K added.
- The largest Kiora Pharmaceuticals seller in Q2 2019 was Virtu Financial, an estimated $16.2K sold.
Based on aggregated 13F filings for Q2 2019.